The anti-angiogenic activity of genistein is also investigated in prostate cancer, where it downregulates the genes level of uPAR, MMP-9, VEGF, neuropilin, TSP-1, TSP, TGF-β2, BPGF, PAR-2, protease M, and LPA. This evidence concerns the gene THBS1 and prostate carcinoma.